Racemic vs. enantiopure inert Ti(iv) complex of a single diaminotetrakis(phenolato) ligand in anticancer activity toward human drug-sensitive and -resistant cancer cell lines

Maya Miller, Edit Y. Tshuva*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

A tetrakis(phenolato) Ti(iv) complex was synthesized in racemic and optically pure form, exhibiting high hydrolytic stability, and similar cytotoxicity for all stereochemical forms on HT-29 and A2780 cancer cells. Higher activity of the racemate on drug-resistant A2780cp and A2780adr lines implies a beneficial activity of both enantiomers rendering enantiomeric resolution unnecessary.

Original languageAmerican English
Pages (from-to)39731-39734
Number of pages4
JournalRSC Advances
Volume8
Issue number69
DOIs
StatePublished - 2018

Bibliographical note

Funding Information:
We thank Dr Benny Bogoslavsky for solution of the X-ray structure. Funding was received from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement 681243).

Publisher Copyright:
© The Royal Society of Chemistry.

Fingerprint

Dive into the research topics of 'Racemic vs. enantiopure inert Ti(iv) complex of a single diaminotetrakis(phenolato) ligand in anticancer activity toward human drug-sensitive and -resistant cancer cell lines'. Together they form a unique fingerprint.

Cite this